PubMed · 41165026
Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.
Abstract
Hematologic malignancies are cancers that affect the bone marrow, lymphatic system, and hematopoietic cells, resulting in various cancer subtypes and clinical manifestations. Currently, tissue biopsy in hematological malignancies is typically performed for genomic profiling and has limitations such as invasiveness, lengthy procedures, and high expense. On the other hand, liquid biopsy serves as an emerging tool used for examining the blood or other bodily fluids of patients, for the purpose of identifying genetic mutations, biomarkers, or cancer-related substances. Liquid biopsy biomarkers include circulating tumor DNA (ctDNA), microRNA (miRNA), and exosomes. In the context of hematological malignancies, these biomarkers offer valuable insights into disease etiology, enabling effective disease monitoring and guiding treatment decisions owing to their differential expression patterns. This review critically examines the recent advancements and effectiveness of liquid biopsy biomarkers in the areas of diagnosis, therapy, and monitoring. The challenges and future directions of liquid biopsy for hematological malignancies are also discussed.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Al-Yafie Shikaha Ahmed Y, Lee Wei Shyn, Pong Ben Jun Xiang, Rajendran Dhanusha, Tesfagin Reem Michael, Wei Hsum Yap, Bey Hing Goh, Rebecca Shin-Yee Wong. 2025-10-30. Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.. https://doi.org/10.1111/ajco.70038
Cite the original work for its findings. Save a collection to share your selection of sources.